Galcanezumab: Difference between revisions
| [unchecked revision] | [unchecked revision] |
Create Galcanezumab page |
MDElliottMD (talk | contribs) Category taxonomy ship: retag Migraine Medicines -> Antimigraine agents |
||
| Line 19: | Line 19: | ||
[[Category:CGRP Monoclonal Antibodies]] | [[Category:CGRP Monoclonal Antibodies]] | ||
[[Category:CGRP-targeting Migraine Medicines]] | [[Category:CGRP-targeting Migraine Medicines]] | ||
[[Category: | [[Category:Antimigraine agents]] | ||
Latest revision as of 00:36, 22 May 2026
Anti-CGRP ligand monoclonal antibody
Galcanezumab
Emgality
Galcanezumab (brand name Emgality) is a humanized monoclonal antibody targeting the CGRP peptide, FDA-approved in 2018 for migraine prevention and in 2019 for episodic cluster headache prevention.
Experience
No personal reports yet
No clinical reports yet
Log in to add your own experience.
Problems
No problems yet. Be the first to suggest one.
+ Add a problemTitration strategies
No titration strategies yet. Be the first to suggest one.
Effects
No effects listed yet. Be the first to suggest one.
Relevant anecdote
No anecdotes yet. Share a relevant one.
Relevant Literature
No literature entries yet.
Log in to submit relevant literature.
Summary
Classes
Anti-CGRP ligand monoclonal antibody
Common uses
Preventive treatment of migraine in adults; episodic cluster headache
Pharmacy
Starting dose
Migraine: 240 mg SC loading dose, then 120 mg SC monthly. Cluster: 300 mg SC at onset of cluster period, then monthly during cluster.
Preparations
120 mg/mL prefilled syringe or autoinjector
US FDA Max
240 mg loading + 120 mg/month for migraine; 300 mg/month for cluster
Pharmacology
Routes
Subcutaneous
Onset
Over weeks
Duration
Monthly dosing
Half-life
~27 days
Bioavailability
Not formally established (high SC)
Pregnancy
Limited data; avoid
Legal status
Rx
Purported mechanism
Humanized IgG4 monoclonal antibody binding CGRP peptide; prevents CGRP from activating its receptor